FTC, Surmodics and cardiovascular devicemaker

FTC sues to block medical device coatings deal
The Federal Trade Commission under President Trump is making its first move to challenge private equity in health care, by suing to block the $627 million acquisition of a maker of specialized coatings for catheters and other medical devices.
FTC sues to block Surmodics acquisition by private equity over device coating competition
The FTC said merging Surmodics with Biocoat, where GTCR has a majority stake, would result in one company with more than 50% of the hydrophilic coating market.
FTC challenges private equity firm’s acquisition of Surmodics
The U.S. Federal Trade Commission (FTC) has sued to block the planned acquisition of medical device company Surmodics (Nasdaq:SRDX) by GTCR.
FTC sues to block acquisition of Surmodics
The Federal Trade Commission announced it has sued to block GTCR BC Holdings’ acquisition of Surmodics (SRDX), alleging that the deal, which
FTC Moves to Block Surmodics-GTCR Merger Over Healthcare Cost Concerns
The U.S. Federal Trade Commission (FTC) has filed a lawsuit to prevent medical device coatings maker Surmodics from merging with private equity firm GTCR, citing concerns over rising healthcare costs.
Surmodics drops after FTC files suit to block its planned sale to GTCR
Surmodics (NASDAQ:SRDX) fell 4.6% after the Federal Trade Commission filed a lawsuit to block its planned $627 million sale to private equity firm GTCR. The FTC filed suit in the U.S. District Court for the Northern District of Illinois,
FTC sues to block GTCR’s $627M Surmodics acquisition
The agency is challenging the deal, citing antitrust concerns due to GTCR's existing ownership of Surmodics' rival Biocoat.
FTC challenges $627M private equity takeover of Surmodics
The regulator said the buyout “would lead to a highly concentrated market for outsourced hydrophilic coatings and eliminate ...
Surmodics (NASDAQ:SRDX) Upgraded at Lake Street Capital
Lake Street Capital upgraded shares of Surmodics (NASDAQ:SRDX – Free Report) from a hold rating to a buy rating in a report published on Friday morning, Marketbeat.com reports. Lake Street Capital ...
Surmodics upgraded to Buy from Hold at Lake Street
Lake Street analyst Brooks O’Neil upgraded Surmodics (SRDX) to Buy from Hold with an unchanged price target of $43. The Federal Trade ...
Surmodics Issues Statement on U.S. Federal Trade Commission Challenge to Proposed Acquisition of Surmodics by Funds Affiliated with GTCR
Surmodics, Inc. (Nasdaq: SRDX), a provider of medical device and in vitro diagnostic technologies to the healthcare industry, ...
Crain's Chicago Business2d
FTC targets GTCR in agency's first merger challenge under new Trump term
The regulator says the proposed merger would give the combined company more than 50% of the market for a type of medical ...
PE Hub2d
Surmodics says it will defend proposed acquisition by GTCR against FTC lawsuit
The Federal Trade Commission on March 6 sued to block GTCR’ s acquisition of Surmodics, alleging that “the deal, which seeks to combine the two largest manufacturers of critical medical device ...
Why Surmodics Stock Is Falling On Friday
Surmodics stock drops 4.76% in premarket trading following news that the FTC will challenge its proposed acquisition by GTCR.
Surmodics drops on report it will meet with regulators to try to save deal
Surmodics (NASDAQ:SRDX) edged lower by 0.7% amid a report that it's scheduled to meet with regulators this week to convince ...
Zacks Investment Research on MSN2d
SRDX Stock Falls Following Plan for Legal Action Against FTC Challenge
Surmodics, Inc. SRDX recently provided a statement in response to the U.S. Federal Trade Commission (“FTC”) blocking the ...